At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BYSI Beyondspring Inc
Not Yet Opened 12-20 16:00:00 EST
1.59
+0.04
+2.58%
盘后1.59
+0.000.00%
16:00 EST
High1.60
Low1.50
Vol68.06K
Open1.55
D1 Closing1.55
Amplitude6.45%
Mkt Cap64.08M
Tradable Cap40.19M
Total Shares40.30M
T/O103.56K
T/O Rate0.27%
Tradable Shares25.28M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
BRIEF-Beyondspring Presents Efficacy/Safety Results From A Phase 2 Study Of Pembrolizumab Plus Plinabulin/Docetaxel In Metastatic Nsclc After Progressing On First-Line Immune Checkpoint Inhibitors At Esmo Congress 2024
Beyondspring Presents Efficacy/Safety Results From a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on First-Line Immune Checkpoint Inhibitors at Esmo Congress 2024
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
Beyondspring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During Esmo Congress 2024 Showcasing Its Lead Anti-Cancer Asset, Plinabulin
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.